银诺医药-B已在中国完成核心产品(即依苏帕格鲁肽α)用于治疗肥胖和超重的III期临床试验的首例患者给药

Core Insights - The company, Silver诺医药-B (02591), has announced the initiation of the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions [1] Company Developments - The clinical trial is set to recruit approximately 800 participants in China [1]